Fundz

Corvus Pharmaceuticals, Inc.

Burlingame, California, United States · Biopharma, Biotechnology, Healthcare

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company

Key facts

Headquarters
Burlingame, California, United States
Employees
Unknown
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (CRVS)
Website
corvuspharma.com

Recent activity at Corvus Pharmaceuticals, Inc.

  • : SEC 8-K (5.02): On July 21, 2026, Ian T. Clark notified Corvus Pharmaceuticals, Inc. of his decision to resign from the board of directors, with his resignation effective as of July 22, 2026. Mr. Clark served on the board for over nine years, and the Company expressed gratitude for his significant contributions during his tenure. This change could impact the board's strategic direction and governance, as the Company will need to fill the vacancy left by Mr. Clark's departure following his extensive service.
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.02): On April 22, 2026, Corvus Pharmaceuticals, Inc. appointed Andrew C. Chan, M.D., Ph.D., as a Class II director, effective April 23, 2026, with a term expiring at the 2027 annual meeting. Dr. Chan will receive a $35,000 annual retainer and an initial stock option grant of 30,000 shares under the company's 2016 Equity Incentive Award Plan, along with additional cash for serving on the Nominating Committee. Concurrently, Scott Morrison has notified the Board of his resignation, effective April 23, 2026, ending over a decade of service. This change highlights a shift in leadership dynamics within the Board.
  • : SEC 8-K (1.01): On March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC to sell up to $200,000,000 of the Company's common stock. This agreement amends a prior agreement from August 6, 2024, which had an offering limit of $100,000,000. The Company has not sold any shares under the original agreement, and the amended agreement allows Jefferies to facilitate the sale of shares through various methods, with a commission of up to 3.0% on gross sales. Additionally, the Company has agreed to indemnify Jefferies against certain liabilities under federal securities laws. This development potentially enhances the Company’s ability to raise capital through stock sales in the market.
  • : SEC 8-K (8.01): On January 21, 2026, Corvus Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC for a public offering of 7,900,677 shares of its common stock at a public offering price of $22.15 per share. The Underwriters will purchase the shares at a price of $20.821 per share, and have an option to purchase an additional 1,185,101 shares, which they exercised in full on January 22, 2026. The offering is expected to close on January 23, 2026, with net proceeds expected to be approximately $188.3 million to be used for working capital and general corporate purposes, including capital expenditures and various clinical trials. The agreement includes standard provisions such as representations, warranties, closing conditions, and obligations related to liabilities under the Securities Act.
  • : SEC 8-K (8.01): This filing describes the encouraging results from cohort 4 of a clinical trial evaluating soquelitinib for inflammatory and immune diseases, with data collected until January 15, 2026. Cohort 4 involved a total of 24 patients randomized to receive either soquelitinib or placebo over a 56-day treatment period. The study found significant safety and efficacy results, with a mean percent reduction in Eczema Area and Severity Index (EASI) of 70% in soquelitinib patients compared to 40% in the placebo group at day 56. The Company aims to initiate a Phase 2 trial for moderate to severe atopic dermatitis based on these positive outcomes, showcasing the potential of soquelitinib in treating patients resistant to prior therapies. The strategic implications highlight the drug’s novel mechanism targeting multiple T cell pathways, emphasizing its promise in the market for treatments addressing immune disorders.
  • : SEC 8-K (8.01): On January 20, 2026, Corvus Pharmaceuticals, Inc. suspended its proposed registered underwritten public offering of common stock, which was to be conducted under the Open Market Sale Agreement with Jefferies LLC. The agreement allowed for the sale of up to $100 million in common stock, but prior to the suspension, no shares had been sold and all shares remained available. The suspension means the Company will not proceed with any sales under the current agreement unless a new prospectus is filed. This decision highlights the Company’s caution in navigating market conditions related to the offering.
  • : SEC 8-K (8.01): On January 20, 2026, Corvus Pharmaceuticals, Inc. announced the suspension of its proposed registered underwritten public offering of common stock. This decision was communicated to Jefferies LLC, the underwriter, and relates to a previous Sale Agreement established on August 6, 2024, which permitted the sale of up to $100 million of common stock under a shelf registration statement. Prior to this suspension, no shares had been sold under the agreement, and all $100 million worth of shares remained available for future transactions. The strategic implications of this suspension indicate a potential adjustment in the company's capital raising strategy.
  • : Corvus Pharmaceuticals Publishes Preclinical Data on Soquelitinib for Tumor Immunity Modulation
  • : Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Corvus Pharmaceuticals, Inc. funding history

DateRoundAmount
Sep 2015Venture$75.0M

Leadership

  • Jeffrey Arcara, Chief Business Officer

Verified email and direct lines for Corvus Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Corvus Pharmaceuticals, Inc. in the news

Companies similar to Corvus Pharmaceuticals, Inc.

  • vTv Therapeutics Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • MBX Biosciences, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • OnKure Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • Mereo Biopharma Group plc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics

About Corvus Pharmaceuticals, Inc.: questions and answers

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company

Where is Corvus Pharmaceuticals, Inc. headquartered?

Corvus Pharmaceuticals, Inc. is headquartered in Burlingame, California, United States.

Has Corvus Pharmaceuticals, Inc. raised funding?

Yes. Fundz has recorded 1 funding event for Corvus Pharmaceuticals, Inc.. The most recent, $75.0M, was in Sep 2015.

What is the latest news on Corvus Pharmaceuticals, Inc.?

On Jan 20, 2026, SEC 8-K (5.02): On July 21, 2026, Ian T. Clark notified Corvus Pharmaceuticals, Inc. of his decision to resign from the board of directors, with his resignation effective as of July 22, 2026. Mr. Clark served on the board for over nine years, and the Company expressed gratitude for his significant c

Is Corvus Pharmaceuticals, Inc. a public company?

Yes. Corvus Pharmaceuticals, Inc. is publicly traded under the ticker CRVS.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Corvus Pharmaceuticals, Inc. across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.